Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6209 Relative Bioavailability and Food Effect Study in Healthy Participants
NCT07610148Phase 1Active, not recruiting
- Sponsor
- Hengrui
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRS-6209 in breast cancer (3 arms), sponsored by Hengrui. Primary endpoints: Area under the concentration time curve and Maximum Plasma Concentration. Started Jun 2026; status: active, not recruiting.
02
Drugs
HRS-6209
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07610148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610148.